Acadia Healthcare Hits New 52-Week High at $31.35, Signaling Recovery

Acadia Healthcare Co., Inc. has reached a significant milestone by hitting a new 52-week high of USD 31.35 on July 1, 2026. This achievement marks a notable recovery for the small-cap company, which operates within the Pharmaceuticals & Biotechnology sector. Despite the recent uptick in stock price, Acadia Healthcare's one-year performance reflects a decline of 55.09%, contrasting sharply with the S&P 500's gain of 20.74% over the same period. The company's market capitalization stands at USD 2,113 million, indicating its position as a small-cap player in the industry. Financial metrics reveal a price-to-earnings (P/E) ratio of 10.00, suggesting a valuation that may attract attention in the context of its sector. Additionally, Acadia Healthcare's return on equity is reported at 10.39%, while its price-to-book ratio is 1.08. The company currently does not offer a dividend yield, and its debt-to-equity ratio is 1.23, reflecting its financial leverage. This new high could signal a pivotal moment for Acadia Healthcare as it navigates the evolving landscape of the pharmaceuticals and biotechnology industry.